Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

Pharmacology and Therapeutics

Volumn 142, Issue 2, 2014, Pages 164-175

  Polivka, Jiri ^a,b   Janku, Filip ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Faculty Hospital Plzen   (Czech Republic)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

PI3K pathway; Predictive biomarkers; Targeted therapy

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; APITOLISIB; BIOLOGICAL MARKER; BUPARLISIB; BYL 719; COPANLISIB; DACTOLISIB; EVEROLIMUS; GDC 0032; GSK 2126458; GSK 2141795; IDELALISIB; INK 1117; IPATASERTIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PF 04691502; PF 05212384; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RIDAFOROLIMUS; TEMSIROLIMUS; TENSIN; UNCLASSIFIED DRUG; XL 147; XL 765; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE;

BILIARY TRACT CANCER; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENESIS; COLORECTAL CANCER; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; GENE MUTATION; HUMAN; LIVER CANCER; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY CANCER; PATIENT CARE; PRIORITY JOURNAL; RESPIRATORY TRACT CANCER; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; SMALL INTESTINE CANCER; STOMACH CANCER; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE; URINARY TRACT CANCER; UTERINE CERVIX CANCER;

PI3K PATHWAY; PREDICTIVE BIOMARKERS; TARGETED THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84896401739     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.12.004     Document Type: Review

References (129)

1. M. Addie, P. Ballard, D. Buttar, C. Crafter, G. Currie, and B.R. Davies et al. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases J Med Chem 56 5 2013 2059 2073 10.1021/jm301762v
2. I.U. Agoulnik, M.C. Hodgson, W.A. Bowden, and M.M. Ittmann INPP4B: the new kid on the PI3K block Oncotarget 2 4 2011 321 328
3. D.R. Alessi, S.R. James, C.P. Downes, A.B. Holmes, P.R. Gaffney, and C.B. Reese et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha Curr Biol 7 4 1997 261 269
4. Dario R. Alessi, L.R. Pearce, and J.M. García-Martínez New insights into mTOR signaling: mTORC2 and beyond Sci Signal 2 67 2009 pe27 10.1126/scisignal.267pe27
5. M. Andjelković, D.R. Alessi, R. Meier, A. Fernandez, N.J. Lamb, and M. Frech et al. Role of translocation in the activation and function of protein kinase B J Biol Chem 272 50 1997 31515 31524
6. A. Aslam, and I.H. Coulson Cowden syndrome (multiple hamartoma syndrome) Clin Exp Dermatol 2013 10.1111/ced.12140
7. J. Baselga, M. Campone, M. Piccart, H.A. Burris III, H.S. Rugo, and T. Sahmoud et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 6 2012 520 529 10.1056/NEJMoa1109653
8. A. Bellacosa, D. de Feo, A.K. Godwin, D.W. Bell, J.Q. Cheng, and D.A. Altomare et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas Int J Cancer 64 4 1995 280 285
9. J.C. Bendell, J. Rodon, H.A. Burris, M. de Jonge, J. Verweij, and D. Birle et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors J Clin Oncol 30 3 2012 282 290 10.1200/JCO.2011.36.1360
10. S.V. Bhagwat, P.C. Gokhale, A.P. Crew, A. Cooke, Y. Yao, and C. Mantis et al. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin Mol Cancer Ther 10 8 2011 1394 1406 10.1158/1535-7163.MCT-10-1099
11. B. Blaser, L. Waselle, A. Dormond-Meuwly, M. Dufour, D. Roulin, and N. Demartines et al. Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells BMC Cancer 12 2012 86 10.1186/1471-2407-12-86
12. H.A. Burris III Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway Cancer Chemother Pharmacol 71 4 2013 829 842 10.1007/s00280-012-2043-3
13. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 5573 2002 1655 1657 10.1126/science.296.5573.1655
14. A.M. Cappellano, A.A. Senerchia, F. Adolfo, P.M. Paiva, R. Pinho, and A. Covic et al. Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex Childs Nerv Syst 2013 10.1007/s00381-013-2170-0
15. J.D. Carpten, A.L. Faber, C. Horn, G.P. Donoho, S.L. Briggs, and C.M. Robbins et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer Nature 448 7152 2007 439 444 10.1038/nature05933
16. A. Carracedo, and P.P. Pandolfi The PTEN-PI3K pathway: of feedbacks and cross-talks Oncogene 27 41 2008 5527 5541 10.1038/onc.2008.247
17. J. Carretero, T. Shimamura, K. Rikova, A.L. Jackson, M.D. Wilkerson, and C.L. Borgman et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors Cancer Cell 17 6 2010 547 559 10.1016/j.ccr.2010.04.026
18. cBioPortal for Cancer Genomics Retrieved August 14, 2013, from http://www.cbioportal.org/public-portal/ 2013
19. N. Chalhoub, and S.J. Baker PTEN and the PI3-kinase pathway in cancer Annu Rev Pathol 4 2009 127 150 10.1146/annurev.pathol.4.110807.092311
20. J.Q. Cheng, A.K. Godwin, A. Bellacosa, T. Taguchi, T.F. Franke, and T.C. Hamilton et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas Proc Natl Acad Sci U S A 89 19 1992 9267 9271
21. H. Cheng, E. Merika, K.N. Syrigos, and M.W. Saif Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011 JOP 12 4 2011 334 338
22. L.W.T. Cheung, B.T. Hennessy, J. Li, S. Yu, A.P. Myers, and B. Djordjevic et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability Cancer Discov 1 2 2011 170 185 10.1158/2159-8290.CD-11-0039
23. M. Cheung, and J.R. Testa Diverse mechanisms of AKT pathway activation in human malignancy Curr Cancer Drug Targets 13 3 2013 234 244
24. C.M. Contreras, E.A. Akbay, T.D. Gallardo, J.M. Haynie, S. Sharma, and O. Tagao et al. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy Dis Model Mech 3 3-4 2010 181 193 10.1242/dmm.004440
25. COSMIC (Catalogue of Somatic Mutations in Cancer) Retrieved August 14, 2013, from http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/ 2013
26. S.R. Datta, A. Brunet, and M.E. Greenberg Cellular survival: a play in three Akts Genes Dev 13 22 1999 2905 2927
27. M.A. Davies, K. Stemke-Hale, C. Tellez, T.L. Calderone, W. Deng, and V.G. Prieto et al. A novel AKT3 mutation in melanoma tumours and cell lines Br J Cancer 99 8 2008 1265 1268 10.1038/sj.bjc.6604637
28. F. Di Nicolantonio, S. Arena, J. Tabernero, S. Grosso, F. Molinari, and T. Macarulla et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus J Clin Invest 120 8 2010 2858 2866 10.1172/JCI37539
29. J.A. Engelman Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat Rev Cancer 9 8 2009 550 562 10.1038/nrc2664
30. J.A. Engelman, L. Chen, X. Tan, K. Crosby, A.R. Guimaraes, and R. Upadhyay et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat Med 14 12 2008 1351 1356 10.1038/nm.1890
31. J.A. Engelman, J. Luo, and L.C. Cantley The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat Rev Genet 7 8 2006 606 619 10.1038/nrg1879
32. European Chromosome 16 Tuberous Sclerosis Consortium Identification and characterization of the tuberous sclerosis gene on chromosome 16 Cell 75 7 1993 1305 1315
33. P. Furet, V. Guagnano, R.A. Fairhurst, P. Imbach-Weese, I. Bruce, and M. Knapp et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation Bioorg Med Chem Lett 23 13 2013 3741 3748 10.1016/j.bmcl.2013.05.007
34. J.M. García, J. Silva, C. Peña, V. Garcia, R. Rodríguez, and M.A. Cruz et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer Genes Chromosomes Cancer 41 2 2004 117 124 10.1002/gcc.20062
35. A. Goel, C.N. Arnold, D. Niedzwiecki, J.M. Carethers, J.M. Dowell, and L. Wasserman et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers Cancer Res 64 9 2004 3014 3021
36. D.A. Guertin, and D.M. Sabatini Defining the role of mTOR in cancer Cancer Cell 12 1 2007 9 22 10.1016/j.ccr.2007.05.008
37. D.G. Hardie, F.A. Ross, and S.A. Hawley AMPK: a nutrient and energy sensor that maintains energy homeostasis Nat Rev Mol Cell Biol 13 4 2012 251 262 10.1038/nrm3311
38. K. Hashimoto, N. Mori, T. Tamesa, T. Okada, S. Kawauchi, and A. Oga et al. Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH Mod Pathol 17 6 2004 617 622 10.1038/modpathol.3800107
39. M.P. Hayes, H. Wang, R. Espinal-Witter, W. Douglas, G.J. Solomon, and S.J. Baker et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia Clin Cancer Res 12 20 Pt 1 2006 5932 5935 10.1158/1078-0432.CCR-06-1375
40. B. Hoang, A. Benavides, Y. Shi, Y. Yang, P. Frost, and J. Gera et al. The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance J Biol Chem 287 26 2012 21796 21805 10.1074/jbc.M111.304626
41. D.S. Hong, D.W. Bowles, G.S. Falchook, W.A. Messersmith, G.C. George, and C.L. O'Bryant et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors Clin Cancer Res 18 15 2012 4173 4182 10.1158/1078-0432.CCR-12-0714
42. B.D. Hopkins, B. Fine, N. Steinbach, M. Dendy, Z. Rapp, and J. Shaw et al. A secreted PTEN phosphatase that enters cells to alter signaling and survival Science (New York, N.Y.) 341 6144 2013 399 402 10.1126/science.1234907
43. C.-H. Huang, D. Mandelker, O. Schmidt-Kittler, Y. Samuels, V.E. Velculescu, and K.W. Kinzler et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations Science 318 5857 2007 1744 1748 10.1126/science.1150799
44. G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, and A. Kapoor et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 22 2007 2271 2281 10.1056/NEJMoa066838
45. K. Ichimura, A.P. Vogazianou, L. Liu, D.M. Pearson, L.M. Bäcklund, and K. Plant et al. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas Oncogene 27 14 2008 2097 2108 10.1038/sj.onc.1210848
46. N.T. Ihle, R. Lemos Jr., P. Wipf, A. Yacoub, C. Mitchell, and D. Siwak et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance Cancer Res 69 1 2009 143 150 10.1158/0008-5472.CAN-07- 6656
47. G. Iyer, A.J. Hanrahan, M.I. Milowsky, H. Al-Ahmadie, S.N. Scott, and M. Janakiraman et al. Genome sequencing identifies a basis for everolimus sensitivity Science 338 6104 2012 221 10.1126/science.1226344
48. N. Jaber, Z. Dou, J.-S. Chen, J. Catanzaro, Y.-P. Jiang, and L.M. Ballou et al. Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function Proc Natl Acad Sci U S A 109 6 2012 2003 2008 10.1073/pnas.1112848109
49. M.R. Janes, C. Vu, S. Mallya, M.P. Shieh, J.J. Limon, and L.-S. Li et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia Leukemia 27 3 2013 586 594 10.1038/leu.2012.276
50. F. Janku Bringing target-matched PI3King from the bench to the clinic Cell Cycle 12 12 2013 1817 1818 10.4161/cc.25118
51. F. Janku, R.R. Broaddus, R. Bakkar, D.S. Hong, V.M. Stepanek, and A. Naing et al. PTEN assessment and PI3K/mTOR inhibitors: importance of simultaneous assessment of MAPK pathway aberrations J Clin Oncol 30 2012 (Supplement)
52. F. Janku, I. Garrido-Laguna, A.M. Tsimberidou, A. Naing, S. Fu, and G.S. Falchook et al. Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors Cancer Res 71 8 2011 10.1158/1538-7445.AM2012-CT-01 (Supplement 1)
53. F. Janku, D.S. Hong, S. Fu, S.A. Piha-Paul, A. Naing, and G.S. Falchook et al. Aberrations in PIK3CA, PTEN, and MAPK (KRAS, NRAS, BRAF) in 1,656 patients and experience with early-phase protocols with PI3K/AKT/mTOR inhibitors Eur J Cancer 48 Supplement 6 2012 76
54. F. Janku, D.J. McConkey, D.S. Hong, and R. Kurzrock Autophagy as a target for anticancer therapy Nat Rev Clin Oncol 8 9 2011 528 539 10.1038/nrclinonc. 2011.71
55. F. Janku, A. Stathis, J. Perez-Garcia, Z. Wainberg, L. Paz-Ares, and J. Vansteenkiste et al. Abstract no. 804: Phase Ib study of oral pan-PI3K BKM120 in combination with the oral MEK1/2 inhibitor GSK120212 in patients with selected advanced solid tumors and RAS/BRAF mutations Presented at the European Cancer Congress 2013, Amsterdam 2013
56. F. Janku, A.M. Tsimberidou, I. Garrido-Laguna, X. Wang, R. Luthra, and D.S. Hong et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors Mol Cancer Ther 10 3 2011 558 565 10.1158/1535-7163.MCT-10-0994
57. F. Janku, J.J. Wheler, A. Naing, G.S. Falchook, D.S. Hong, and V.M. Stepanek et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials Cancer Res 73 1 2013 276 284 10.1158/0008-5472.CAN-12-1726
58. F. Janku, J.J. Wheler, A. Naing, V.M. Stepanek, G.S. Falchook, and S. Fu et al. PIK3CA mutations in advanced cancers: characteristics and outcomes Oncotarget 3 12 2012 1566 1575
59. F. Janku, J.J. Wheler, S.N. Westin, S.L. Moulder, A. Naing, and A.M. Tsimberidou et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations J Clin Oncol 30 8 2012 777 782 10.1200/JCO.2011.36.1196
60. S. Jia, Z. Liu, S. Zhang, P. Liu, L. Zhang, and S.H. Lee et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis Nature 454 7205 2008 776 779 10.1038/nature07091
61. D. Juric, G. Argiles, H.A. Burris, A.M. Gonzalez-Angulo, C. Saura, and C. Quadt et al. Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC) Cancer Res 72 24 2012 10.1158/0008-5472.SABCS12-P6-10-07 (Supplement 3)
62. D. Juric, J. Rodon, A.M. Gonzalez-Angulo, H.A. Burris, J.C. Bendell, and J.D. Berlin et al. BYL719, a next generation PI3K alpha specific inhibitor: preliminary safety, PK, and efficacy results from the first-in-human study Cancer Res 72 8 2012 10.1158/1538-7445.AM2012-CT-01 (Supplement 1)
63. S. Kang, S.S. Seo, H.J. Chang, C.W. Yoo, S.Y. Park, and S.M. Dong Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma Int J Gynecol Cancer 18 6 2008 1339 1343 10.1111/j.1525-1438.2007.01172.x
64. C. Knuefermann, Y. Lu, B. Liu, W. Jin, K. Liang, and L. Wu et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells Oncogene 22 21 2003 3205 3212 10.1038/sj.onc.1206394
65. M.H. Kohrman Emerging treatments in the management of tuberous sclerosis complex Pediatr Neurol 46 5 2012 267 275 10.1016/j.pediatrneurol.2012.02.015
66. K. Kok, B. Geering, and B. Vanhaesebroeck Regulation of phosphoinositide 3-kinase expression in health and disease Trends Biochem Sci 34 3 2009 115 127 10.1016/j.tibs.2009.01.003
67. S.K. Kuwada, and R. Burt A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome Fam Cancer 10 3 2011 469 472 10.1007/s10689-011-9471-9
68. V. Launonen Mutations in the human LKB1/STK11 gene Hum Mutat 26 4 2005 291 297 10.1002/humu.20222
69. J.O. Lee, H. Yang, M.M. Georgescu, A. Di Cristofano, T. Maehama, and Y. Shi et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association Cell 99 3 1999 323 334
70. J. Li, C. Yen, D. Liaw, K. Podsypanina, S. Bose, and S.I. Wang et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 5308 1997 1943 1947
71. J. Lin, D. Sampath, M.A. Nannini, B.B. Lee, M. Degtyarev, and J. Oeh et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models Clin Cancer Res 19 7 2013 1760 1772 10.1158/1078-0432.CCR-12-3072
72. P. Liu, H. Cheng, T.M. Roberts, and J.J. Zhao Targeting the phosphoinositide 3-kinase pathway in cancer Nat Rev Drug Discov 8 8 2009 627 644 10.1038/nrd2926
73. V.W.Y. Lui, M.L. Hedberg, H. Li, B.S. Vangara, K. Pendleton, and Y. Zeng et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers Cancer Discov 3 7 2013 761 769 10.1158/2159-8290.CD-13- 0103
74. L. Ma, N. Niknejad, I. Gorn-Hondermann, K. Dayekh, and J. Dimitroulakos Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells PloS one 7 9 2012 e46055 10.1371/journal.pone.0046055
75. I.M. Macias-Perez, and I.W. Flinn GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia Curr Hematol Malig Rep 8 1 2013 22 27 10.1007/s11899-012-0142-1
76. T. Maehama, and J.E. Dixon The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate J Biol Chem 273 22 1998 13375 13378
77. D. Mahadevan, E.G. Chiorean, W.B. Harris, D.D. Von Hoff, A. Stejskal-Barnett, and W. Qi et al. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies Eur J Cancer 48 18 2012 3319 3327 10.1016/j.ejca.2012.06.027
78. C.L. Mahoney, B. Choudhury, H. Davies, S. Edkins, C. Greenman, and G. van Haaften et al. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition Br J Cancer 100 2 2009 370 375 10.1038/sj.bjc.6604886
79. B.D. Manning, and L.C. Cantley Rheb fills a GAP between TSC and TOR Trends Biochem Sci 28 11 2003 573 576 10.1016/j.tibs.2003.09.003
80. B. Markman, R. Dienstmann, and J. Tabernero Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs Oncotarget 1 7 2010 530 543
81. I.A. May, J.M. Balko, M.G. Kuba, M.E. Sanders, J. Yap, and Y. Li et al. PD09-05: SU2C phase Ib study of pan-PI3K inhibitor BKM120 plus aromatase inhibitor letrozole in ER+/HER2- metastatic breast cancer (MBC) Cancer Res 71 24 2011 10.1158/0008-5472.SABCS11-PD09-05 (Supplement 3)
82. F.X. McCormack, Y. Inoue, J. Moss, L.G. Singer, C. Strange, and K. Nakata et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis N Engl J Med 364 17 2011 1595 1606 10.1056/NEJMoa1100391
83. W. Miwa, J. Yasuda, Y. Murakami, K. Yashima, K. Sugano, and T. Sekine et al. Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer Biochem Biophys Res Commun 225 3 1996 968 974 10.1006/bbrc.1996.1280
84. R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, and S. Bracarda et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 9637 2008 449 456 10.1016/S0140-6736(08)61039-9
85. G. Nagaraj, X.M. Cynthia, L. Jingqin, and J.E. Matthew A phase I study of BKM120, a novel oral selective phosphatidylinositol-3-kinase (PI3K) inhibitor, in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer J Clin Oncol 30 2012 (Supplement; abstr TPS664)
86. A. Naing, C. Aghajanian, E. Raymond, D. Olmos, G. Schwartz, and E. Oelmann et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma Br J Cancer 107 7 2012 1093 1099 10.1038/bjc.2012.368
87. J. Ni, Q. Liu, S. Xie, C. Carlson, T. Von, and K. Vogel et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent Cancer Discov 2 5 2012 425 433 10.1158/2159-8290.CD- 12-0003
88. K.E. O'Reilly, F. Rojo, Q.-B. She, D. Solit, G.B. Mills, and D. Smith et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 3 2006 1500 1508 10.1158/0008-5472.CAN-05-2925
89. S. Ogita, and P. Lorusso Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs Target Oncol 6 2 2011 103 117 10.1007/s11523-011- 0176-7
90. S.K. Pal, K. Reckamp, H. Yu, and R.A. Figlin Akt inhibitors in clinical development for the treatment of cancer Expert Opin Investig Drugs 19 11 2010 1355 1366 10.1517/13543784.2010.520701
91. A. Papa, M. Chen, and P.P. Pandolfi Pills of PTEN? In and out for tumor suppression Cell Research 23 10 2013 1155 1156 10.1038/cr.2013.103
92. S.A. Piha-Paul, D.S. Hong, and R. Kurzrock Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus)-based treatment J Clin Oncol 29 12 2011 e333 e335 10.1200/JCO.2010.32.5928
93. K.G. Pike, K. Malagu, M.G. Hummersone, K.A. Menear, H.M.E. Duggan, and S. Gomez et al. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014 Bioorg Med Chem Lett 23 5 2013 1212 1216 10.1016/j.bmcl.2013.01.019
94. J. Polivka Jr., J. Polivka, V. Rohan, O. Topolcan, and J. Ferda New molecularly targeted therapies for glioblastoma multiforme Anticancer Res 32 7 2012 2935 2946
95. G. Prasad, T. Sottero, X. Yang, S. Mueller, C.D. James, and W.A. Weiss et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide Neuro Oncol 13 4 2011 384 392 10.1093/neuonc/noq193
96. U. Putz, J. Howitt, A. Doan, C.-P. Goh, L.-H. Low, and J. Silke et al. The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells Science Signaling 5 243 2012 ra70 10.1126/scisignal.2003084
97. L.S. Pymar, F.M. Platt, J.M. Askham, E.E. Morrison, and M.A. Knowles Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms Hum Mol Genet 17 13 2008 2006 2017 10.1093/hmg/ddn098
98. C.P. Reynolds, M.H. Kang, H. Carol, R. Lock, R. Gorlick, and E.A. Kolb et al. Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program Pediatr Blood Cancer 60 5 2013 791 798 10.1002/pbc.24301
99. J. Rodon, R. Dienstmann, V. Serra, and J. Tabernero Development of PI3K inhibitors: lessons learned from early clinical trials Nat Rev Clin Oncol 10 3 2013 143 153 10.1038/nrclinonc.2013.10
100. V.S. Rodrik-Outmezguine, S. Chandarlapaty, N.C. Pagano, P.I. Poulikakos, M. Scaltriti, and E. Moskatel et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling Cancer Discov 1 3 2011 248 259 10.1158/2159-8290.CD-11-0085
101. B.A. Ruggeri, L. Huang, M. Wood, J.Q. Cheng, and J.R. Testa Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas Mol Carcinog 21 2 1998 81 86
102. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, and S. Szabo et al. High frequency of mutations of the PIK3CA gene in human cancers Science 304 5670 2004 554 10.1126/science.1096502
103. T. Sato, A. Nakashima, L. Guo, K. Coffman, and F. Tamanoi Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer Oncogene 29 18 2010 2746 2752 10.1038/onc.2010.28
104. D.B. Shackelford, E. Abt, L. Gerken, D.S. Vasquez, A. Seki, and M. Leblanc et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin Cancer Cell 23 2 2013 143 158 10.1016/j.ccr.2012.12.008
105. R.J. Shaw, and L.C. Cantley Ras, PI(3)K and mTOR signalling controls tumour cell growth Nature 441 7092 2006 424 430 10.1038/nature04869
106. R.J. Shaw, M. Kosmatka, N. Bardeesy, R.L. Hurley, L.A. Witters, and R.A. DePinho et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress Proc Natl Acad Sci U S A 101 10 2004 3329 3335 10.1073/pnas.0308061100
107. Y. Shi, B.E. Paluch, X. Wang, and X. Jiang PTEN at a glance J Cell Sci 125 Pt 20 2012 4687 4692 10.1242/jcs.093765
108. T.A. Smolarek, L.L. Wessner, F.X. McCormack, J.C. Mylet, A.G. Menon, and E.P. Henske Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis Am J Hum Genet 62 4 1998 810 815 10.1086/301804
109. L. So, S.S. Yea, J.S. Oak, M. Lu, A. Manmadhan, and Q.H. Ke et al. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function J Biol Chem 288 8 2013 5718 5731 10.1074/jbc.M112.379446
110. M.S. Song, L. Salmena, and P.P. Pandolfi The functions and regulation of the PTEN tumour suppressor Nat Rev Mol Cell Biol 13 5 2012 283 296 10.1038/nrm3330
111. J.M. Stahl, A. Sharma, M. Cheung, M. Zimmerman, J.Q. Cheng, and M.W. Bosenberg et al. Deregulated Akt3 activity promotes development of malignant melanoma Cancer Res 64 19 2004 7002 7010 10.1158/0008-5472.CAN-04-1399
112. P.A. Steck, M.A. Pershouse, S.A. Jasser, W.K. Yung, H. Lin, and A.H. Ligon et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers Nat Genet 15 4 1997 356 362 10.1038/ng0497-356
113. L.R. Stephens, A. Eguinoa, H. Erdjument-Bromage, M. Lui, F. Cooke, and J. Coadwell et al. The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101 Cell 89 1 1997 105 114
114. D.F. Stern ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer J Mammary Gland Biol Neoplasia 13 2 2008 215 223 10.1007/s10911-008-9083-7
115. S.-Y. Sun mTOR kinase inhibitors as potential cancer therapeutic drugs Cancer Lett 2013 10.1016/j.canlet.2013.06.017
116. J.A. Sznol, L.B. Jilaveanu, and H.M. Kluger Studies of NVP-BEZ235 in melanoma Curr Cancer Drug Targets 13 2 2013 165 174
117. M. Van Slegtenhorst, R. de Hoogt, C. Hermans, M. Nellist, B. Janssen, and S. Verhoef et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34 Science 277 5327 1997 805 808
118. B. Vanhaesebroeck, J. Guillermet-Guibert, M. Graupera, and B. Bilanges The emerging mechanisms of isoform-specific PI3K signalling Nat Rev Mol Cell Biol 11 5 2010 329 341 10.1038/nrm2882
119. K.M. Vasudevan, D.A. Barbie, M.A. Davies, R. Rabinovsky, C.J. McNear, and J.J. Kim et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer Cancer Cell 16 1 2009 21 32 10.1016/j.ccr.2009.04.012
120. A.J. Wagner, I. Malinowska-Kolodziej, J.A. Morgan, W. Qin, C.D.M. Fletcher, and N. Vena et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors J Clin Oncol 28 5 2010 835 840 10.1200/JCO.2009.25.2981
121. J.J. Wallin, K.A. Edgar, J. Guan, M. Berry, W.W. Prior, and L. Lee et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway Mol Cancer Ther 10 12 2011 2426 2436 10.1158/1535-7163.MCT-11-0446
122. B. Weigelt, P.H. Warne, and J. Downward PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs Oncogene 30 29 2011 3222 3233 10.1038/onc.2011.42
123. A. Wiestner Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2012 88 96 10.1182/asheducation-2012.1.88
124. M. Yalon, L. Ben-Sira, S. Constantini, and A. Toren Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex Childs Nerv Syst 27 1 2011 179 181 10.1007/s00381-010-1222-y
125. J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, and E. Van Cutsem et al. Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 6 2011 514 523 10.1056/NEJMoa1009290
126. T.A. Yap, L. Yan, A. Patnaik, I. Fearen, D. Olmos, and K. Papadopoulos et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors J Clin Oncol 29 35 2011 4688 4695 10.1200/JCO.2011.35.5263
127. Z. Zeng, Y.X. Shi, T. Tsao, Y. Qiu, S.M. Kornblau, and K.A. Baggerly et al. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment Blood 120 13 2012 2679 2689 10.1182/blood-2011-11-393934
128. L. Zhao, and P.K. Vogt Class I PI3K in oncogenic cellular transformation Oncogene 27 41 2008 5486 5496 10.1038/onc.2008.244
129. Li Zhao, and P.K. Vogt Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms Proc Natl Acad Sci U S A 105 7 2008 2652 2657 10.1073/pnas.0712169105